Survival and prognostic association in stage IV colorectal cancer patients treated with chemotherapy in Bangladesh

被引:0
作者
Shuayb, Md [1 ,4 ]
Hasan, Md Mehedi [1 ]
Hoque, Md Rashedul [2 ]
Hussain, Qazi Mushtaq [3 ]
Begum, Rabeya [2 ]
Reza, Md Salim [1 ]
机构
[1] Sq Hosp Ltd, Sq Oncol & Radiotherapy Ctr, Dhaka, Bangladesh
[2] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada
[3] Natl Inst Canc Res & Hosp, Dhaka, Bangladesh
[4] Univ British Columbia, Vancouver Gen Hosp, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada
关键词
chemotherapy; colorectal cancer; colon cancer; rectal cancer; survival; prognostic factor; FACTORS PREDICTING SURVIVAL; PERITONEAL CARCINOMATOSIS; TRIALS; DETERMINANTS; RESECTION; OUTCOMES;
D O I
10.1093/jjco/hyaa228
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Prognostic factors in colorectal cancer have lesser been evaluated in developing countries. This study aims to determine overall survival and prognostic factors for metastatic colorectal cancer patients who were non-operable and received chemotherapy. Methods: The study retrospectively investigated 67 inoperable metastatic colorectal cancer patients at Square Hospital, Bangladesh. The primary endpoint was overall survival, and the secondary endpoints were prognostic association with factors. Survival probabilities were calculated by non-parametric Kaplan-Meier method and compared by log-rank test. Univariate and multivariable Cox proportional hazard models were implemented to assess the prognostic association. Results: Median survival of the entire cohort was 14 months (95% confidence interval: 11-25). In multivariable analysis, two prognostic factors were independently associated with survival: Karnofsky performance status and carcinoembryonic antigen. Patients with Karnofsky performance status <70 had significant higher risk of death than those with Karnofsky performance status =70 (adjusted hazard ratio 4.25, 95% confidence interval: 2.15-8.39). Higher risk of deathwas found to be associated with higher carcinoembryonic antigen: adjusted hazard ratio was 1.72 (95% confidence interval: 0.81-3.68) and 2.96 (95% confidence interval: 1.25-7.01) for patients with carcinoembryonic antigen 10-100 and >100 ng/ml, respectively, while comparing with carcinoembryonic antigen <10 ng/ml. The presence of peritoneal metastasis and grade-III tumour significantly worsened the survival in univariate analysis (hazard ratio 2.46, 95% confidence interval: 1.32-4.57 and hazard ratio 1.74, 95% confidence interval: 1.01-3.03, respectively) but not in multivariable analysis (adjusted hazard ratio 1.92, 95% confidence interval: 0.88-4.18 and adjusted hazard ratio 1.25, 95% confidence interval: 0.66-2.36, respectively). Conclusion: The study reported survival of stage IV colorectal cancer patients undergo chemotherapy and identified that Karnofsky performance status and carcinoembryonic antigen are the poor prognostic factors to this cohort adjusting for other factors.
引用
收藏
页码:552 / 559
页数:8
相关论文
共 30 条
[1]  
Colon Cancer, 2019, NCCN CLIN PRACT GUID
[2]  
Davidov D, 2017, J IMAB, V23, P1532, DOI 10.5272/jimab.2017232.1532
[3]   PROGNOSTIC FACTORS OF ADVANCED COLORECTAL-CANCER PATIENTS [J].
EDLER, L ;
HEIM, ME ;
QUINTERO, C ;
BRUMMER, T ;
QUEISSER, W .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (10) :1231-1237
[4]  
Ferlay J, 2021, Global Cancer Observatory: Cancer Today
[5]  
Field K, 2007, WORLD J GASTROENTERO, V13, P3806
[6]   Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer - Analysis of 1001 consecutive cases [J].
Fong, Y ;
Fortner, J ;
Sun, RL ;
Brennan, MF ;
Blumgart, LH .
ANNALS OF SURGERY, 1999, 230 (03) :309-318
[7]   Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database [J].
Franko, Jan ;
Shi, Qian ;
Meyers, Jeffrey P. ;
Maughan, Timothy S. ;
Adams, Richard A. ;
Seymour, Matthew T. ;
Saltz, Leonard ;
Punt, Cornelis J. A. ;
Koopman, Miriam ;
Tournigand, Christophe ;
Tebbutt, Niall C. ;
Diaz-Rubio, Eduardo ;
Souglakos, John ;
Falcone, Alfredo ;
Chibaudel, Benoist ;
Heinemann, Volker ;
Moen, Joseph ;
De Gramont, Aimery ;
Sargent, Daniel J. ;
Grothey, Axel .
LANCET ONCOLOGY, 2016, 17 (12) :1709-1719
[8]   Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 [J].
Franko, Jan ;
Shi, Qian ;
Goldman, Charles D. ;
Pockaj, Barbara A. ;
Nelson, Garth D. ;
Goldberg, Richard M. ;
Pitot, Henry C. ;
Grothey, Axel ;
Alberts, Steven R. ;
Sargent, Daniel J. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) :263-267
[9]   The continuum of care: A paradigm for the management of metastatic colorectal cancer [J].
Goldberg, Richard M. ;
Rothenberg, Mace L. ;
Van Cutsem, Eric ;
Benson, Al B., III ;
Blanke, Charles D. ;
Diasio, Robert B. ;
Grothey, Axel ;
Lenz, Heinz-Josef ;
Meropol, Neal J. ;
Ramanathan, Ramesh K. ;
Becerra, Carlos H. Roberto ;
Wickham, Rita ;
Armstrong, Delma ;
Viele, Carol .
ONCOLOGIST, 2007, 12 (01) :38-50
[10]   DETERMINANTS OF PROGNOSIS IN ADVANCED COLORECTAL-CANCER [J].
GRAF, W ;
GLIMELIUS, B ;
PAHLMAN, L ;
BERGSTROM, R .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (09) :1119-1123